Skip to main content
. 2011 Nov 9;2(11):850–861. doi: 10.18632/oncotarget.347

Figure 3. Impact of idarubicin in 156 AML patients ≤ 60y according to DNMT3A exon 23 mutations.

Figure 3

DFS (A) and OS (B) according to daunorubicin or idarubicin treatment. DFS (C) and OS (D) in patients treated by idarubicin according to DNMT3A exon 23 mutations. DFS (E) and OS (F) in patients treated by daunorubicin according to DNMT3A exon 23 mutations.